Oxaliplatin, a platinum analogue employed in the treatment of colorectal cancer and various other neoplasms, is characterized by a broad range of adverse events. Peripheral neuropathy is probably the most peculiar and clinically relevant toxicity associated with its use and can be distinguished into two types: acute and chronic neurotoxicity. We report a case of acute reversible bilateral palpebral ptosis and dyspnea without bronchospasm or laryngospasm which occurred at the end of the third administration of adjuvant oxaliplatin by infusion for stage III colon cancer in a 54-year-old woman. Chlorphenamine and hydrocortisone were administered with fast resolution of dyspnea and slight improvement of ptosis. Complete resolution with no sequelae occurred in one hour. No further recurrence of blepharoptosis was described during the following days. The subsequent cycles were prescribed at reduced dosage without acute complications.
HoffP.M., SaadE.D., CostaF., CoutinhoA.K., CaponeroR., ProllaG., GanslR.C.: Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer, 11: 93–100, 2012.
2.
RaymondE., FaivreS., WoynarowskiJ.M., ChaneyS.G.: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol, 25: 4–12, 1998.
AmptoulachS., TsavarisN.: Neurotoxicity caused by the treatment with platinum analogues (review article). Chemother Res Pract, 2011: 843019, 2011.
5.
de GramontA., FigerA., SeymourM.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18: 2938–2947, 2000.
6.
AndréT., BoniC., NavarroM., TaberneroJ., HickishT., TophamC., BonettiA., ClinganP., BridgewaterJ., RiveraF., de GramontA.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27: 3109–3116, 2009.
7.
AndréT., BoniC., Mounedji-BoudiafL., NavarroM., TaberneroJ., HickishT., TophamC., ZaninelliM., ClinganP., BridgewaterJ., Tabah-FischI., de GramontA.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350: 2343–2351, 2004.
8.
GamelinE., GamelinL., BossiL., QuasthoffS.: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol, 29: 21–33, 2002.
9.
LucchettaM., LonardiS., BergamoF., AlbertiP., VelascoR., ArgyriouA.A., BrianiC., BrunaJ., CazzanigaM., CortinovisD., CavalettiG., KalofonosH.P.: Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol, 70: 899–902, 2012.
10.
GiacchettiS., PerpointB., ZidaniR., Le BailN., FaggiuoloR., FocanC., CholletP., LloryJ.F., LetourneauY., CoudertB., Bertheaut-CvitkovicF., Larregain-FournierD., Le RolA., WalterS., AdamR., MissetJ.L., LéviF.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol, 18: 136–147, 2000.
11.
GrotheyA., GoldbergR.M.: A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother, 5: 2159–2170, 2004.
12.
ArgyriouA.A., VelascoR., BrianiC., CavalettiG., BrunaJ., AlbertiP., CacciavillaniM., LonardiS., SantosC., CortinovisD., CazzanigaM., KalofonosH.P.: Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol, 23: 3116–3122, 2012.
13.
GamelinL., CapitainO., MorelA., DumontA., TraoreS., Le BouilA., GillesS., Boisdron-CelleM., GamelinE.: Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res, 13: 6359–6368, 2007.
TournigandC., CervantesA., FigerA., LledoG., FleschM., BuyseM., MineurL., CarolaE., EtienneP.L., RiveraF., ChirivellaI., Perez-StaubN., LouvetC., AndréT., Tabah-FischI., de GramontA.: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol, 24: 394–400, 2006.
16.
DurandJ.P., DeplanqueG., MontheilV., GornetJ.M., ScotteF., MirO., CessotA., CoriatR., RaymondE., MitryE., HeraitP., YatagheneY., GoldwasserF.: Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol, 23: 200–205, 2012.
17.
La VerdeN., GarassinoM.C., SpinelliG., ScanniA., SburlatiP., FarinaG., LabiancaR.: Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis, 39: 1041, 2007.
18.
SaifM.W., HashmiS.: Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol, 61: 349–354, 2008.
